Insys Therapeutics, Inc. (INSY)

4.21
NASDAQ
Prev Close 4.21
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.35 / 11.65
Exchange NASDAQ
Shares Outstanding 74.43B
Market Cap 313.34M
Div & Yield N.A. (N.A)
INSYS Therapeutics Completes Pharmacokinetics (PK) Study Of Intranasal Naloxone For Opioid Overdose

INSYS Therapeutics Completes Pharmacokinetics (PK) Study Of Intranasal Naloxone For Opioid Overdose

Results Show Favorable Effect of Company's Novel Formulation, Similar to Intramuscular Administration; NDA Filing with FDA on Track for 2018

INSYS Therapeutics Files New Drug Application (NDA) For Buprenorphine Sublingual Spray With FDA

INSYS Therapeutics Files New Drug Application (NDA) For Buprenorphine Sublingual Spray With FDA

Advances R&D for promising portfolio of innovative medicines

Insiders Now Seeing Red With INSY At New 52-Week Low

Insiders Now Seeing Red With INSY At New 52-Week Low

In trading on Monday, shares of Insys Therapeutics Inc touched a new 52-week low of $8.68/share. That's a $6.38 share price drop, or -42.36% decline from the 52-week high of $15.06 set back on 11/10/2016.

INSYS Therapeutics Hires First Corporate Communications Leader And New Investor Relations Agency

INSYS Therapeutics Hires First Corporate Communications Leader And New Investor Relations Agency

Increases commitment to engaging key stakeholder groups as Company continues development of pharmaceutical cannabinoids

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARCI, GRC, HDNG, PLPC Downgrades: AFI, CXW, DEL, HBMD, INSY, JCAP, MET, NGVC, PLT, SATS, STRL, UHS, VRTV, WP Initiations: PI, VRS Read on to get TheStreet Quant Ratings' detailed report:

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)

Jim Cramer says the calendar and the momentum holders are coalescing to produce selling. Here's what investors should do about it.

Insys Therapeutics Shares Cross Below 200 DMA

Insys Therapeutics Shares Cross Below 200 DMA

In trading on Friday, shares of Insys Therapeutics Inc crossed below their 200 day moving average of $11.34, changing hands as low as $11.17 per share. Insys Therapeutics Inc shares are currently trading off about 1.6% on the day.

September 15th Options Now Available For Insys Therapeutics (INSY)

September 15th Options Now Available For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

Alder Shares Plummet Almost 25% Despite Positive Data; Aralez Pops on Patent Victory: Biotech Movers

Alder Shares Plummet Almost 25% Despite Positive Data; Aralez Pops on Patent Victory: Biotech Movers

Alder BioPharmaceuticals, Aralez Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on June 27.

Interesting INSY Put And Call Options For February 2018

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the February 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."

Launch of Cannabis ETF May Not Be Best Option for Investors

Launch of Cannabis ETF May Not Be Best Option for Investors

Although a cannabis ETF launched in April, investors are still likely to find more value in buying individual stocks in the sector, according to traders.

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

INSY Crosses Above Average Analyst Target

In recent trading, shares of Insys Therapeutics Inc have crossed above the average analyst 12-month target price of $14.00, changing hands for $14.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Insys Therapeutics, Inc. Announces FDA Final Product Label For Syndros

Launch Planned for August 2017

INSY: Insiders vs. Shorts

The most recent short interest data was recently released for the 04/28/2017 settlement date, and Insys Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 20.51 "days to cover" versus the median component at 4.80. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Raytheon, Celgene, Orbital ATK, CenturyLink: 'Mad Money' Lightning Round

Raytheon, Celgene, Orbital ATK, CenturyLink: 'Mad Money' Lightning Round

Jim Cramer is bullish on Raytheon, Celgene, and Orbital ATK; he's bearish on CenturyLink and Pennsylvania Real Estate Investments.

TheStreet Quant Rating: D (Sell)